20mins delayed


1 Year Return

Exopharm Ltd Chart

Share price
Market Cap $19.14 million
Today's Movement
Prev. Close
Day Range -
Historical Stats
52w Range -
4w Avg Volume
4w Avg Turnover

EX1 Statistics

15 July

1,493 / 2,232

ASX Size Rank

1yr Return

vs Sector (1yr)


vs ASX 200 (1yr)


$19.14 million

Market Cap

Share Issue

59.81 million

All Ords (%)


Short Sold


Current Fundamentals

15 July


PE Ratio

EPS ($)


Earnings Yield


NTA ($)



Dividend Yield

DPS ($)


Gross Div. Yield


Gross DPS ($)


Company Overview

Exopharm Limited (EX1) is an Australian biopharmaceutical company that deals in developing regenerative medicine, primarily being the development and de-risking of exosome technologies, particularly the LEAP manufacturing process and development of the PlexarisTM and ExomereTM products.

Exopharm Ltd Logo

Corporate Details

Head Office: Melbourne
Managing Director: Ian Dixon
GICS Sub-Industry: Biotechnology
Date Listed: 18 Dec 2018
Registry: Automic
Similar Companies: CSL / MSB / CUV / PAR / OPT

Upcoming Calendar

Dividend History

Ex-Date Amount Franking Type Payable
No dividends paid in the last 5 years

See Upcoming Dividends for all ASX companies.


Date Heading Pages File Size Time

Broker Consensus

The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.

EX1 is not covered by a major broker,
or data from most recent compilation was omitted due
to not meeting QA guidelines.

Directors & Management

About the Data

Name Title Since Bio
Mr David Rodney Parker Non-Executive Director Jun 2018
Dr Ian Edward Dixon Company Founder, Technology Co-Founder, Managing Director May 2013
Mr Jason Mark Watson Non-Executive Chairman, Non-Executive Director Aug 2018

Director Transactions

About the Data

EX1 directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
13/09/19 Jason Watson Issued 100,000 $0.370 $37,000 Placement.
19/08/19 David Parker Buy +20,000 $0.370 $7,400 Participation in share purchase plan.
19/08/19 Ian Dixon Buy +40,000 $0.370 $14,800 Participation in share purchase plan.
19/08/19 Jason Watson Buy +40,000 $0.370 $14,800 Participation in share purchase plan.

Shareholder Distribution

About the Data

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over Total Shareholders
No. of Shareholders 21 80 125 549 166 941

Top 20 Shareholders

About the Data

Name Shares Capital
Altnia Holdings Pty Ltd (Dixon Family A/C) 27,975,294 29.33%
Mr Michael Francis Mcmahon & Mrs Susan Lesley Mcmahon (Mcmahon Super Fund A/C) 2,310,000 2.42%
Oldview Enterprises Pty Ltd (The Priestley A/C) 1,476,963 1.55%
Anthony John Locantro 1,330,000 1.39%
Carda Pty Ltd (Carda Super Fund A/C) 1,220,000 1.28%
Phytose Corporation Pty Limited (Boundaryone Super A/C) 1,176,471 1.23%
Pabasa Pty Ltd (Kehoe Family Super Fund A/C) 1,000,000 1.05%
Mrs Anna Felicia Belton 978,334 1.03%
Acns Capital Markets Pty Ltd 810,000 0.85%
Drp 2006 Super Pty Ltd (Drp (2006) Super Fund A/C) 760,000 0.80%
Basapa Pty Ltd (Kehoe Family A/C) 750,000 0.79%
Kohen Enterprises Pty Ltd 750,000 0.79%
Lonhro (Wa) Pty Ltd (Lonhro A/C) 736,667 0.74%
Saintly Company Pty Ltd (Walker Investment A/C) 670,000 0.70%
Mr Andrew Stewart Coles & Ms Alexandra Constance Manook (Coles Family Super A/C) 615,000 0.64%
Gregor Lichtfuss 588,235 0.62%
Mr Anthony De Nicola & Mrs Tanya Louise De Nicola (De Nicola Family S/F A/C) 575,000 0.60%
Jeccs Pty Ltd (Brown Family No1 A/C) 547,000 0.57%
Labonne Enterprises Pty Ltd (Mcintyre Family A/C) 500,000 0.52%
Ringsford Pty Ltd (Dg & Gl Walker S/F A/C) 500,000 0.52%
All other shareholders 52.58 %

The Top 20 Shareholders of EX1 hold 47.42% of shares on issue.

EX1 Share Price History

Date Close Change % Change Open High Low Volume Turnover

EX1 Historical Data

Download up to 20 years of share price history.

Year Closing Price (30 June) Last Trade
2019 $0.41 28 June

Offical data as published by ASX. See more Data Downloads.

Company Details

Principal Activity: Developing regenerative medicine, primarily being the development and de-risking of exosome technologies, particularly the LEAP manufacturing process and development of the Plexaris and Exomere products.

Incorporated: --

Level 17, 31 Queen St
Melbourne VIC 3000

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.